Breast

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Leave a Comment / Genetics / By

By Denise Mann Health Day Reporter (Health Day) FRIDAY, Dec. 9, 2022 (HealthDay News) — A new genetic test could help determine which people with breast cancer can safely skip radiation after breast-conserving surgery to remove their tumor. People with invasive breast cancer who had low scores on an experimental gene panel were just as …

Genetic test could help some breast cancer patients avoid radiation after lumpectomy Read More »

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Genetic test could help some breast cancer patients avoid radiation after lumpectomy

Leave a Comment / Genetics / By

FRIDAY, Dec. 9, 2022 (HealthDay News) — A new genetic test could help determine which people with breast cancer can safely skip radiation after breast-conserving surgery to remove their tumor. People with invasive breast cancer who had low scores on an experimental gene panel were just as likely to experience a recurrence whether or not …

Genetic test could help some breast cancer patients avoid radiation after lumpectomy Read More »

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model

Leave a Comment / Genetics / By

Myriad Genetics, Inc. Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model Read More »

Livestock Improvement: How Forward Pack and Sexed Semen Can Boost Genetic Gain | MarketScreener

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener

Leave a Comment / Genetics / By

Myriad’s MyRisk™ hereditary cancer test with RiskScore® provides personalized breast cancer risk assessment for women of all backgrounds SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model | MarketScreener Read More »

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model

Leave a Comment / Genetics / By

SALT LAKE CITY, 08 Dec. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a simple standard of care risk assessment. The data was shared …

Myriad Genetics Patient Outcome Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction Than Standard Risk Model Read More »

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

Leave a Comment / Genetics / By

NEW YORK – For patients whose HER2-negative and hormone receptor-positive metastatic breast cancers progress after treatment with combination CDK4/6 inhibitors and hormone therapy, there is no additional benefit to continuing treatment with Pfizer Ibrance’s CDK4/6 inhibitor (palbociclib) plus another hormone therapy as the next line of treatment, suggest phase II study results presented at the …

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors Read More »

Race may affect breast cancer outcomes in women with similar genetic recurrence scores

Leave a Comment / Genetics / By

06 December 2022 3 minute read Source/Disclosures Published by: Source: Abdou Y, et al. Abbreviated GS1-01. Presented at: San Antonio Breast Cancer Symposium; December 10, 6-10, 2022; Saint Anthony. Disclosures: NIH, NCI, Susan G. Komen for the Cure Research Program, Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health (now Exact Sciences …

Race may affect breast cancer outcomes in women with similar genetic recurrence scores Read More »

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Leave a Comment / Genetics / By

A featured discussion sheds light on how the Combined Risk Score can lead to better breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new data presentations at the San Antonio Breast Cancer …

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment Read More »

HALO Diagnostics Partners with Ikonopedia to Offer Comprehensive Women's Health Genetic Testing to Improve Early Detection of Breast Cancer

HALO Diagnostics Partners with Ikonopedia to Offer Comprehensive Women’s Health Genetic Testing to Improve Early Detection of Breast Cancer

Leave a Comment / Genetics / By

Integrated approach supposed to triple early detection in high-risk women; Five-year survival rate increases to 99% with early diagnosis LOS GATOS, CA. and RICHARDSON, TX, November 28, 2022 /PRNewswire/ — HALO Diagnostics, the leader in early disease detection using precision diagnostics, and Ikonopedia, a next-generation breast imaging tracking and reporting solution, today announced a genetic …

HALO Diagnostics Partners with Ikonopedia to Offer Comprehensive Women’s Health Genetic Testing to Improve Early Detection of Breast Cancer Read More »

CRISPR vs breast, colon and lung cancer: first-in-human trial going well

CRISPR vs breast, colon and lung cancer: first-in-human trial going well

Leave a Comment / Genetics / By

Share on PinterestIn a small trial, researchers have used gene-editing technology for the first time to treat breast, colon and lung cancer in humans. Image credit: Andrew Brookes/Getty Images. For the first time, researchers have used CRISPR technology to substitute genes in patients’ immune cells to treat cancer. Participants included 16 patients with different solid …

CRISPR vs breast, colon and lung cancer: first-in-human trial going well Read More »